<a href="https://laohu8.com/S/PYXS">Pyxis Oncology</a> reports $77.7 million in cash and cash equivalents as of September 30, 2025
Pyxis Oncology Inc. reported a net loss of $22.0 million, or $0.35 per common share, for the quarter ended September 30, 2025, compared to a net loss of $21.2 million, or $0.35 per common share, for the same period in 2024. Excluding non-cash stock-based compensation expense, the net loss was $18.9 million for the quarter, versus $18.2 million for the prior year quarter. As of September 30, 2025, the company held $77.7 million in cash, cash equivalents, and short-term investments, with an expected cash runway into the second half of 2026. Business developments include ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma, with preliminary data expected in the fourth quarter of 2025. As of October 31, 2025, Pyxis Oncology had 62.3 million shares of common stock outstanding.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567005-en) on November 03, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.